Last reviewed · How we verify
Succitimal — Competitive Intelligence Brief
marketed
phensuximide
Voltage-gated T-type calcium channel
Neuroscience
Small molecule
Live · refreshed every 30 min
Target snapshot
Succitimal (PHENSUXIMIDE).
Comparator set (2 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Succitimal TARGET | PHENSUXIMIDE | marketed | phensuximide | Voltage-gated T-type calcium channel | 1982-01-01 | |
| Celontin | METHSUXIMIDE | Pfizer | marketed | Anti-epileptic Agent | Voltage-gated T-type calcium channel | 1957-01-01 |
| Paradione | PARAMETHADIONE | marketed | paramethadione | Voltage-gated T-type calcium channel | 1949-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (phensuximide class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Succitimal CI watch — RSS
- Succitimal CI watch — Atom
- Succitimal CI watch — JSON
- Succitimal alone — RSS
- Whole phensuximide class — RSS
Cite this brief
Drug Landscape (2026). Succitimal — Competitive Intelligence Brief. https://druglandscape.com/ci/phensuximide. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing